MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.